Outcome of the Board Meeting
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 3.9 pts less than Nifty Microcap 250 and 4.1 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
The board, which met on May 28, 2025, approved audited standalone and consolidated financial results for Q4 and FY ended March 31, 2025. Full-year revenue from operations was nearly flat at Rs. 6,719.24 lakhs versus Rs. 6,728.07 lakhs in FY24, while full-year profit after tax rose about 6% to Rs. 154.89 lakhs (FY24: Rs. 146.07 lakhs), translating to EPS of Rs. 1.60. Q4 was softer, with revenue at Rs. 1,406.92 lakhs (down ~9.8% YoY) and PAT of Rs. 32.64 lakhs (down ~45% YoY). The board recommended a final dividend of Rs. 0.80 per share (8% on face value of Rs. 10). Additionally, the company has sold its entire stake in wholly owned subsidiary Sandu Phytoceuticals Private Limited (struck off from MCA records in September 2024), so no consolidation is required going forward. New Secretarial Auditor (Swapnil J Dixit & Associates for 5 years) and Cost Auditor (Shekhar Joshi & Co for FY26) were appointed, and the reclassification of promoter Akshath Finvest and Properties (holding 4,94,182 shares, 5.12%) to public category was approved.
Shareholders will receive an 8% final dividend subject to AGM approval, supported by positive operating cash flows of Rs. 95 lakhs in FY25. The subsidiary divestment simplifies the group structure, while the mixed Q4 performance (revenue and profit decline) versus steady full-year numbers suggests a watch on near-term momentum.